Abstract
British pharmaceutical giant GlaxoSmithKline was lauded in headlines for its recent announcement that it would voluntarily act to improve access to medicines in developing countries. But will GSK's measures really enhance the health of the global poor?
| Original language | English |
|---|---|
| Specialist publication | Policy Innovations Digital Magazine |
| Publication status | Published - 4 Mar 2009 |